FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Efficacy was evaluated in a single-arm cohort of PLEIADES study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1586 results
Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients with CUP
The results from an open-label phase II study in patients with carcinoma of unknown primary
Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond Delayed CINV
The results from a head-to-head comparison of two different neurokinin-1 receptor antagonists for the prevention of chemotherapy induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Long-Term Outcomes from the CheckMate 067 Study in Patients With Advanced Melanoma
Longest median overall survival in a phase III melanoma study reported to date and the first report of melanoma-specific survival
FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumour
Efficacy was evaluated in AMPECT study in patients with locally advanced unresectable or metastatic malignant PEComa
Withdrawal of Application to Change the EU Marketing Authorisation for Cervarix
Withdrawal concerns application to use Cervarix in individuals from the age of 9 years for the prevention of head and neck cancers
Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer
The results from a randomised, phase III DAWNA-1 study with a new, orally administered, selective CDK4/6 inhibitor
ctDNA-Guided Therapy with Pertuzumab plus Trastuzumab for HER2-Amplified mCRC
Results from the first prospective study showing that patients with HER2-amplified metastatic colorectal cancer identified by ctDNA genotyping benefit from dual-HER2 blockade similarly to patients identified by conventional tissue analysis
EMA Recommends Granting a Conditional Marketing Authorisation for Sotorasib
It is intended for the treatment of patients with advanced NSCLC with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy
FDA Approves Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma
Evidence for efficacy is based on the results from the KEYNOTE-564 study
EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices on the Planning and Conduct of Registry-Based Studies
Generating high-quality evidence from registry-based studies
FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia
Evidence for efficacy is based on the results from the ASCEMBL and CABL001X2101 studies